Paclitaxel liposomal - Syncore Biotechnology

Drug Profile

Paclitaxel liposomal - Syncore Biotechnology

Alternative Names: EndoTAG-1; MBT-0206; SB 05

Latest Information Update: 27 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of California at San Francisco
  • Developer Jules Bordet Institute; MediGene AG; SynCore Biotechnology
  • Class Antineoplastics; Diterpenes; Paclitaxels; Small molecules; Taxanes
  • Mechanism of Action Angiogenesis inhibitors; Mitosis inhibitors; Platelet-derived growth factor inhibitors; Proto-oncogene protein c-bcl-2 inhibitors; Tubulin inhibitors; Tubulin polymerisation promoters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Pancreatic cancer
  • New Molecular Entity No
  • Available For Licensing Yes - Pancreatic cancer

Highest Development Phases

  • Phase III Breast cancer; Pancreatic cancer
  • No development reported Colorectal cancer; Gastrointestinal cancer; Liver cancer; Prostate cancer

Most Recent Events

  • 11 Jun 2018 Phase-III clinical trials in Pancreatic cancer (Late-stage disease, Metastatic disease, Combination therapy, Second-line therapy or greater) in Taiwan (IV) (NCT03126435)
  • 19 Apr 2017 SynCore Biotechnology plans a phase III trial for Pancreatic cancer (Late-stage disease, Second-line therapy or greater, Combination therapy, Metastatic disease) in USA, Israel, Taiwan, Spain, Russia, Hungary, South Korea, France, Romania and Czechia (NCT03126435)
  • 01 Nov 2016 Phase-III clinical trials in Breast cancer (Metastatic disease, First-line therapy, Combination therapy) in Taiwan (IV) (NCT03002103)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top